Trillium Therapeutics (Trillium Therapeutics) Long-Term Debt : $0.00 Mil (As of Sep. 2021)

View and export this data going back to 2009. Start your Free Trial

What is Trillium Therapeutics Long-Term Debt?

Trillium Therapeutics's Long-Term Debt for the quarter that ended in Sep. 2021 was $0.00 Mil.

Trillium Therapeutics Long-Term Debt Historical Data

The historical data trend for Trillium Therapeutics's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Trillium Therapeutics Long-Term Debt Chart

Trillium Therapeutics Annual Data

Trend

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Long-Term Debt

Get a 7-Day Free Trial

0.14

Trillium Therapeutics Quarterly Data
	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21
Long-Term Debt	Get a 7-Day Free Trial															-	-	-	-	-

Trillium Therapeutics (NAS:TRIL) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Trillium Therapeutics Long-Term Debt Related Terms

Thank you for viewing the detailed overview of Trillium Therapeutics's Long-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Trillium Therapeutics (Trillium Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Trillium Therapeutics Inc (NAS:TRIL) » Definitions » Long-Term Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

100 CambridgePark Drive, Suite 510, Cambridge, MA, USA, 02140

Website

https://www.trilliumtherapeutics.com

Trillium Therapeutics Inc is a clinical-stage immuno-oncology company that is engaged in developing therapies for the treatment of cancer. It has two clinical programs, TTI-621 and TTI-622, that target CD47. The company operates in the United States and Canada.